Interleukin-6 signaling pathway in targeted therapy for cancer.
about
Current status of biomarkers for prostate cancerDNA Repair and Cytokines: TGF-β, IL-6, and Thrombopoietin as Different Biomarkers of RadioresistancePotential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisPotential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancerPredictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Complement and macrophage crosstalk during process of angiogenesis in tumor progressionParaneoplastic thrombocytosis: the secrets of tumor self-promotionTargeting the tumor microenvironment: JAK-STAT3 signalingNuclear factor kappa B role in inflammation associated gastrointestinal malignanciesSOCS, inflammation, and cancerSTAT3: A Novel Molecular Mediator of Resistance to ChemoradiotherapyTargeted immune therapy of ovarian cancerTumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategiesInterleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistanceA randomized trial of diet and physical activity in women treated for stage II-IV ovarian cancer: Rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): An NRG Oncology/Gynecologic Oncology Group (GOG-225) SIl-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migrationFUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression dataThe role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma.Regulation of cytotoxicity and apoptosis-associated pathways contributes to the enhancement of efficacy of cisplatin by baicalein adjuvant in human A549 lung cancer cells.STAT3 and epithelial-mesenchymal transitions in carcinomasOvarian cancer cell heparan sulfate 6-O-sulfotransferases regulate an angiogenic program induced by heparin-binding epidermal growth factor (EGF)-like growth factor/EGF receptor signalingGenetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy.A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.Health Promoting Life-Style Behaviors and Systemic Inflamma-tion in African American and Caucasian Women Prior to Chemo-therapy for Breast CancerInterleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell functionTissue polypeptide antigen & interleukin-6: Are their serum levels a predictor for response to chemotherapy in breast cancer?Dietary energy balance modulates ovarian cancer progression and metastasis.AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.Resveratrol Inhibits IL-6-Induced Transcriptional Activity of AR and STAT3 in Human Prostate Cancer LNCaP-FGC Cells.Impact of interleukin-6 in hematological malignancies.Pericellular proteolysis in cancerMinocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas.Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway.Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.The role of cytokines in breast cancer development and progressionCoexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.Serum glucose and risk of cancer: a meta-analysis.
P2860
Q24600574-F1D11FE8-061A-4CBD-BCB1-68C8F73CF4F1Q26738556-8C3506A0-CF8F-4C78-A96A-8DE2974A4EFEQ26746099-6E42EB76-F86E-4175-A1E1-65D20097333AQ26769917-13302B42-4664-401B-9DFD-5E622D9E90F8Q26784218-69866B71-12D0-4398-BE0B-E753575B78AEQ26801339-99EA435E-48E7-4EE0-8FF0-EBE4BEA2FD93Q26825427-5AC35F98-520A-4639-92AE-83006E8610F6Q26825658-4F303F1D-61DE-4B04-BB7D-83A79EDC7C1AQ26865584-8754A0F3-E733-4845-A644-C88B2BBC4063Q26991808-F7A85023-09DF-4C8D-9E42-9626127B10FCQ27003190-B706CA9F-7E4F-4E14-863A-A78692C94048Q28082828-D5849AD3-1FF6-4ADE-B8F0-4A03D7944B57Q28085631-BE96FC53-8512-438C-8DF6-292B686F526CQ28504893-929BAA22-7A6C-46E5-9715-B8035AC8DF1FQ30355266-6340F7FA-430E-4B43-89DC-EEBA5D61B7CFQ30660919-4EE3C76A-EB37-4B73-8D70-C526801DF859Q30711138-AAD34DDD-D860-4EBF-A5BF-2B0657D3E482Q33589279-8DAC7F8A-FEB5-4A1C-8FEB-D8CE78F856E4Q33597807-6E88F33F-E72D-44E9-90F7-27E1C562FCDCQ33623947-DAEC91F7-0399-4EB0-9528-6B491B60EFE2Q33675726-25D67C17-8269-471F-9E68-F4E6724317EDQ33714950-DB2A8674-3C7D-4E76-8D7A-61D4356AEA14Q33820227-23F45381-BFEF-4E50-9331-63E7D61D6FD6Q33870701-E5A3413A-7897-455F-999C-2F7516A3469AQ34003403-B5B2AD14-7E23-4691-A5A3-3CD3DE948895Q34057935-90F13463-84CF-42AF-9EE6-83FC2DB50923Q34176287-7095D3B9-293A-4A7B-9D13-4048B09010D6Q34227594-4924135B-EF7F-4D9F-9601-FBCC08A377DDQ34334399-21B40F0C-93EB-4CA4-8491-682A910D6E65Q34360539-8621D79C-F6F0-4E1F-A8A4-1C6663038658Q34387624-FE9D73FD-2243-4804-B04F-8D62A7BD7627Q34430691-EB2860A7-AE72-42E8-81A7-C52FF7DA66C1Q34674172-66F9BCB7-021C-4725-81CB-D8B9D91B8C3EQ34695303-3E23F03A-D38B-4709-B282-9DAFD983F4F3Q34729901-6BE4B064-368B-46E8-9B8C-F652E2DB433EQ34806348-396258BE-4216-4368-81A9-0A3569BD6309Q34920381-E5555A28-B94D-4D7D-835F-D8009EAB4E52Q35020913-C36DF84C-3E03-4BF5-8843-F2FA737FB7DCQ35058009-FDC635D3-3CA8-4DBF-8FBE-4A3679652638Q35059999-F3EE11AB-2194-474E-9ADD-B49C7504C515
P2860
Interleukin-6 signaling pathway in targeted therapy for cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Interleukin-6 signaling pathway in targeted therapy for cancer.
@en
type
label
Interleukin-6 signaling pathway in targeted therapy for cancer.
@en
prefLabel
Interleukin-6 signaling pathway in targeted therapy for cancer.
@en
P2093
P1476
Interleukin-6 signaling pathway in targeted therapy for cancer.
@en
P2093
TianJian Lu
Zhan Zhang
Zhenfeng Duan
P304
P356
10.1016/J.CTRV.2012.04.007
P577
2012-05-29T00:00:00Z